On May 17, 2021, Aerpio Pharmaceuticals and Aadi Bioscience announced their entry into a definitive merger agreement. Wilson Sonsini Goodrich & Rosati represented Aadi Biosciences in the deal.
Aerpio, a biopharmaceutical company focused on developing compounds that activate Tie2, and Aadi Biosciences, a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, will form a public company that will focus on advancing Aadi’s lead product candidate FYARROTM. Following the proposed merger, Aerpio will change its name to “Aadi Bioscience.”
In support of the merger, Aerpio has entered into subscription agreements to raise $155 million in a Private Investment in Public Equity (PIPE) financing. The PIPE financing is expected to be consummated concurrently with the closing of the merger.
The Wilson Sonsini team advising Aadi includes the following attorneys:
Corporate
Dan Koeppen
Kassandra Castillo
Melissa Freidenreich
Bridget Balisy
M&A
Ethan Lutske
Technology Transactions
Miranda Biven
John Krocak
Colin Bosch
Shefali Tandon
Tony Nguyen
Employee Benefits & Compensation
Matt Norgard
Tax
Myra Sutanto Shen
Nika Antonikova
Regulatory
David Hoffmeister
Eva Yin
Delaware Law
Ryan Greecher
Brian Currie
Please see the related press release for more information.